Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns
Moderna (MRNA) shares experienced volatility following an analyst day where the company provided mixed financial guidance. While management raised its 2026 revenue growth forecast to between 15% and 25%, this projection implies approximately $2.3 billion in sales, which falls short of the $2.4 billion expected by Wall Street analysts. Investors expressed concern regarding long-term capital requirements. Although Moderna is implementing cost-cutting measures for 2026 to improve margins, the company anticipates cash costs will rise significantly to between $4 billion and $4.5 billion annually from 2027 through 2030. This projected increase in burn rate offsets the immediate benefits of current efficiency efforts.
Tickers: $MRNA
Topics: analyst day financial projections profit margins revenue guidance